PetMed Express Reports Q4 2026 Earnings with Declining Sales but Improved Margins
PetMed Express (PETS) reported Q4 net sales of $42.8 million, a 15.6% decline year-over-year due to lower prescription medication sales. However, the company saw sequential growth and improved gross profit margin by 270 basis points to 32.6%. The fiscal year ended with total net sales of $179 million (-21.1%) and a significant net loss of $57.3 million.
Tickers: $PETS
Topics: financial_performance profitability sales